Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules

Cancer Immunology, Immunotherapy

Volumn 56, Issue 2, 2007, Pages 259-269

  So, Tomoko ^a,b   Hanagiri, Takeshi ^b   Chapiro, Jacques ^a,c   Colau, Didier ^a,c   Brasseur, Francis ^a,c   Yasumoto, Kosei ^b   Boon, Thierry ^a,c   Coulie, Pierre G ^a  

^a DE DUVE INSTITUTE   (Belgium)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

Author keywords

Antigen presentation; Cancer; CTL; HLA A24; MAGE

Indexed keywords

GAMMA INTERFERON; GENE PRODUCT; HLA A1 ANTIGEN; HLA A24 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 7; ISOLEUCYLMETHIONYLPROLYLLYSYLALANYLGLYCYLLEUCYLLEUCYLISOLEUCINE; MELANOMA ANTIGEN 3; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ANTIGENICITY; ARTICLE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EPSTEIN BARR VIRUS; GENE EXPRESSION; HLA SYSTEM; HUMAN; HUMAN CELL; MELANOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CLONE CELLS; HLA-A ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; MELANOMA; NEOPLASM PROTEINS; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 33751549706     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-006-0186-y     Document Type: Article

References (24)

1. Akiyama Y, Tanosaki R, Inoue N, Shimada M, Hotate Y, Yamamoto A, Yamazaki N, Kawashima I, Nukaya I, Takesako K, Maruyama K, Takaue Y, Yamaguchi K (2005) Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells. J Transl Med 3:4
2. (+) T cells from melanoma patients reveals inefficient antigen processing. Eur J Immunol 31:2642-2651
3. Bonehill A, Heirman C, Tuyaerts S, Michiels A, Breckpot K, Brasseur F, Zhang Y, Van Der Bruggen P, Thielemans K (2004) Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol 172:6649-6657
4. Chaux P, Vantomme V, Coulie P, Boon T, van der Bruggen P (1998) Estimation of the frequencies of anti-MAGE-3 cytolytic T lymphocyte precursors in blood from individuals without cancer. Int J Cancer 77:538-542
5. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S (2001) An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 61:5544-5551
6. Coulie PG, Karanikas V, Colau D, Lurquin C, Landry C, Marchand M, Dorval T, Brichard V, Boon T (2001) A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA 98:10290-10295
7. De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora J-P, De Smet C, Brasseur F, van der Bruggen P, Lethé B, Lurquin C, Brasseur R, Chomez P, De Backer O, Cavenee W, Boon T (1994) Structure, chromosomal localization and expression of twelve genes of the MAGE family. Immunogenetics 40:360-369
8. Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethé B, Brasseur F, Boon T (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179:921-930
9. Ikeda H, Lethé B, Lehmann F, Van Baren N, Baurain J-F, De Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199-208
10. Karanikas V, Lurquin C, Colau D, van Baren N, De Smet C, Lethé B, Connerotte T, Corbière V, Demoitié M-A, Liénard D, Dréno B, Velu T, Boon T, Coulie PG (2003) Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol 171:4898-4904
11. Kloetzel PM (2001) Antigen processing by the proteasome. Nat Rev Mol Cell Biol 2:179-187
12. Lonchay C, van der Bruggen P, Connerotte T, Hanagiri T, Coulie P, Colau D, Lucas S, Van Pel A, Thielemans K, van Baren N, Boon T (2004) Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci USA 101(Suppl 2):14631-14638
13. Marchand M, Punt CJA, Aamdal S, Escudier B, Kruit WHJ, Keilholz U, Håkansson L, van Baren N, Humblet Y, Mulders P, Avril M-F, Eggermont AMM, Scheibenbogen C, Uiters J, Wanders J, Delire M, Boon T, Stoter G (2003) Immunization of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: clinical report. Eur J Cancer 39:70-77
14. Nakahara S, Tsunoda T, Baba T, Asabe S, Tahara H (2003) Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res 63:4112-4118
15. Nishiyama T, Tachibana M, Horiguchi Y, Nakamura K, Ikeda Y, Takesako K, Murai M (2001) Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin Cancer Res 7:23-31
16. Sadanaga N, Nagashima H, Mashino K, Tahara K, Yamaguchi H, Ohta M, Fujie T, Tanaka F, Inoue H, Takesako K, Akiyoshi T, Mori M (2001) Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 7:2277-2284
17. Tanaka F, Fujie T, Tahara K, Mori M, Takesako K, Sette A, Celis E, Akiyoshi T (1997) Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res 57:4465-4468
18. Triozzi PL, Kim J, Aldrich W (2003) Infusion of unpulsed dendritic cells derived from granulocyte/macrophage colony-stimulating factor-mobilized peripheral blood CD34+ cells and monocytes in patients with advanced carcinoma. J Hematother Stem Cell Res 12:279-287
19. Valmori D, Lienard D, Waanders G, Rimoldi D, Cerottini JC, Romero P (1997) Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. Cancer Res 57:735-741
20. Van den Eynde B, van der Bruggen P Peptide database of T-cell defined tumor antigens. URL: http://www.cancerimmunity.org/peptidedatabase/ Tcellepitopes.htm
21. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-1647
22. van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boel P, De Smet C, Traversari C, Townsend A, Boon T (1994) A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24:3038-3043
23. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM (1999) The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytolytic T lymphocytes. Immunity 10:673-679
24. Zippelius A, Pittet MJ, Batard P, Rufer N, de Smedt M, Guillaume P, Ellefsen K, Valmori D, Liénard D, Plum J, MacDonald HR, Speiser DE, Cerottini J-C, Romero P (2002) Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med 195:485-494